Document Type : Original Article
Firrozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran.
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran
Introduction: We undertook a systematic review of the literature to determine the
efficacy and safety of Imatinib in the restriction of activity and effective treatment of
patients with aggressive fibromatosis (AF) and pigmented villonodular synovitis (PVNS)
and their recurrence.
Method: We searched studies in the PubMed and Cochrane collaborative library at all
levels from 2010 to April 2019. Two independent reviewers evaluated the articles
according to the predefined criteria and extracted the related data. Primary outcomes
associated with tumor size shrinkage, relapse and overall survival along with secondary
outcomes such as pain, quality of life, and side effects were investigated.
Results: 112 studies were evaluated out of which only 6 studies that covered original
studies and case reports were entered into this systematic review. A total of 79subjects
had participated in these six studies with an age range of 22 to 41 years old. In five
studies, participants had a primary tumor and in one research they reported relapse. The
recommended dose was 400 mg/day, which was usually continued for 4 to 12 months.
The tumor size shrinkage and low side effects of drugs have been reported.
Conclusion: According to the results, no systemic treatment for PVNS and AF has been
approved so far, but many studies have demonstrated the efficacy of Imatinib in the
treatment of these diseases. However, further studies are required for optimal treatment
and combined therapies.